Trinity Biotech plc TRIB

Full chart Compare
Set alert

Price alert · TRIB

All alert types
6.56 USD -0.24 (-3.46%)

At closeNov 3, 2026, 4:00 PM EST

6.34 -0.22 -3.35%

After hours · Nov 3, 4:00 PM ET

6.32 Day range 6.80
5.01 52-week range 52.50
YTD
-72.32%
1 year
-77.69%
Market cap
5.33M
Revenue (ttm)
58.65M
Profit margin
-38.01%
EPS (ttm)
-60.00
Shares out
27.52M
Forward P/E
-0.87
YTD return
-72.32%
1-year return
-77.69%
Volume
12.24K
Avg volume
19.24K
Open
6.80
Previous close
6.80
Day's range
6.32 – 6.80
52-week range
5.01 – 52.50
Beta
1.13

1m -0.34 (-5.11%)

6.406.606.80Nov 36.32

Key statistics

Enterprise value
347.37M
PEG ratio
0.00
Price / sales
0.42
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
14.00%
Free cash flow
-9.93M
Total cash
5.32M
Total debt
93.33M
Return on equity
0.00%
Short % of float
2.43%
50-day average
1.39
200-day average
1.90

Next earnings

Consensus EPS estimate -0.30.

Earnings history

Financials — quick view

All financials
TRIB Revenue — quarterly 15.86M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
TRIB Net income — quarterly -16.96M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024

Earnings

TRIB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 15, 2024Sep 1, 2024-0.54-0.43+0.11+20.37%
Aug 14, 2024Jun 1, 2024-0.65-0.55+0.10+15.38%
May 23, 2024Mar 1, 20240.00-0.37——
Apr 4, 2024Dec 1, 20230.00-0.68——
Oct 3, 2023Jun 1, 20230.00-1.00——
Jul 6, 2023Mar 1, 20230.00-0.80——

About Trinity Biotech plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Sector
Healthcare
Industry
Medical Devices
Country
Ireland

News

Your note

Sign in to keep a note on TRIB — it syncs with the Stock Master app.

Institution ownership

TRIB institution ownership
Holder% heldSharesValueReported
Perceptive Advisors Llc79.72%1,800,0001.61MSep 29, 2024
Hunter Associates Investment Management LLC15.93%359,810322.75KSep 29, 2024
Renaissance Technologies, LLC11.08%250,153224.39KSep 29, 2024
Whitefort Capital Management, LP3.63%81,90273.47KSep 29, 2024
Acadian Asset Management. LLC1.85%41,83937.53KSep 29, 2024
HRT Financial LP1.51%34,03030.52KSep 29, 2024

Fund ownership

TRIB fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.22%5,0774.55KOct 30, 2024